Sunday, January 10, 2021 10:21:04 PM
Thank you. If you're ever needing to use an article that discusses or mentions Leronlimab here's a list that I've compiled. I know that I'm missing several still and there will undoubtedly be many more in the future.
https://doi.org/10.1101/2020.05.02.20084673
https://doi.org/10.1093/cid/ciaa1583
https://doi.org/10.1016/j.ijid.2020.10.101
https://doi.org/10.21203/rs.3.rs-26517/v1
https://www.nejm.org/doi/full/10.1056/nejmc2025179
https://www.nejm.org/doi/pdf/10.1056/NEJMc2011117
https://dx.doi.org/10.1016%2Fj.retram.2020.05.004
https://doi.org/10.1016/S2665-9913(20)30340-4
https://doi.org/10.3389/fphar.2020.572870
https://doi.org/10.1155/2020/8827670
https://doi.org/10.1007/s11030-020-10134-x
https://doi.org/10.4155/fmc-2020-0147
https://doi.org/10.1186/s41231-020-00066-x
https://doi.org/10.1002/JLB.3COVR0520-272R
https://doi.org/10.1084/jem.20201342
https://doi.org/10.2147/DDDT.S282252
https://doi.org/10.1158/1538-7445.SABCS19-PD4-04
https://doi.org/10.3233/JAD-200831
https://doi.org/10.1016/j.xkme.2020.06.001
https://doi.org/10.1177%2F0036933020941497
https://journals.lww.com/ccejournal/Fulltext/2020/10000/Clinical_Pharmacists__An_Invaluable_Part_of_the.30.aspx
https://doi.org/10.1101/2020.05.02.20084673
https://doi.org/10.1093/cid/ciaa1583
https://doi.org/10.1016/j.ijid.2020.10.101
https://doi.org/10.21203/rs.3.rs-26517/v1
https://www.nejm.org/doi/full/10.1056/nejmc2025179
https://www.nejm.org/doi/pdf/10.1056/NEJMc2011117
https://dx.doi.org/10.1016%2Fj.retram.2020.05.004
https://doi.org/10.1016/S2665-9913(20)30340-4
https://doi.org/10.3389/fphar.2020.572870
https://doi.org/10.1155/2020/8827670
https://doi.org/10.1007/s11030-020-10134-x
https://doi.org/10.4155/fmc-2020-0147
https://doi.org/10.1186/s41231-020-00066-x
https://doi.org/10.1002/JLB.3COVR0520-272R
https://doi.org/10.1084/jem.20201342
https://doi.org/10.2147/DDDT.S282252
https://doi.org/10.1158/1538-7445.SABCS19-PD4-04
https://doi.org/10.3233/JAD-200831
https://doi.org/10.1016/j.xkme.2020.06.001
https://doi.org/10.1177%2F0036933020941497
https://journals.lww.com/ccejournal/Fulltext/2020/10000/Clinical_Pharmacists__An_Invaluable_Part_of_the.30.aspx
Recent CYDY News
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM

